Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|October 4, 2021
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium StudyHirva Mamdani, Bryan Schneider, Susan M Perkins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 13, 2018
Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trialCatherine E Mosher, Ekin Secinti, Ruohong Li, et al.
Menopause (New York, N.Y.)|May 21, 2009
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapyJulie L Otte, David Flockhart, Daniel Hayes, et al.
Journal of Clinical Medicine|January 11, 2025
Predictive Value of FDG Uptake on PET for Future Immune Checkpoint Inhibitor-Mediated Colitis: A Case SeriesMalek Shatila, Kei Takigawa, Yang Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, et al.
Psycho-Oncology|September 21, 2016
Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibilityCatherine E Mosher, Danielle B Tometich, Adam Hirsh, et al.
Menopause (New York, N.Y.)|March 7, 2009
Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletionJanet S Carpenter, Menggang Yu, Jingwei Wu, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2024
Comparing the rate of immunotherapy treatment change due to toxicity by sexKevin J Chua, Shane Kronstedt, Alain Kaldany, et al.
Gastro Hep Advances|October 27, 2025
Recent Abdominal Surgery as a Risk Factor for Unfavorable Immune-Mediated Colitis OutcomesRohan Ahuja, Malek Shatila, Jay Shah, et al.
Breast Cancer Research and Treatment|May 24, 2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative studyDaneng Li, Linda M McCall, Olwen M Hahn, et al.
Pageof 4